MET and astrocytoma (excluding glioblastoma): The expression status of MET has been studied in the context of IDH mutations and has been found to be a useful prognosis marker, easier to evaluate than chromosome deletion status, correlating with prognosis prediction in IDH mutant astrocytomas and oligodendrogliomas as well as IDH wild-type glioblastomas [75].